NCT01876381已完成2 期
A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 26
- 主要终点
- Change From Baseline in Daily Urine Volume
研究概览
简要总结
To investigate the safety, pharmacokinetics, pharmacodynamics, and efficacy of OPC-41061 in patients with chronic renal failure undergoing hemodialysis or hemodiafiltration using variables, such as daily urine volume and increase in interval body weights between hemodialysis or hemodiafiltration, in 4-day intermittant administration (excluding the days of hemodialysis or hemodiafiltration) at the dose fixed during the dose-escalation period
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration three times a week
- •Subjects between the ages of 20 and 80, inclusive (at time of informed consent)
- •Subjects who are inpatients or who can be admitted to the trial site for the duration of the trial period
- •Subjects who, together with their partner, are able to practice one of the specified contraceptive methods until 4 weeks after the final trial drug administration
- •Patients who are capable of providing written informed consent themselves before any trial-related procedures are performed
排除标准
- •Subjects with a complication of urinary impairment due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
- •Subject with daily urine volume less than 500 mL
- •Subject with Cardiac function of NYHA class 4
- •Subjects with serious ischemic heart disease, who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
- •Subjects with serious arrhythmia, who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
- •Subjects who are concomitantly undergoing peritoneal dialysis
- •Subjects with ascites due to cirrhosis or cancer, requring medical treatments
- •Subjects with any of the following medical histories:
- •History of cerebrovascular disorder or coronary artery disease within 4 weeks prior to informed consent
- •History of hypersensitivity or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride
- •Subjects with any of the following abnormal laboratory values:
- •Hemoglobin lower than 8.0 g/dL, total bilirubin higher than 3.0 mg/dL, ALT (GPT) or AST (GOT) 2 times the upper limit of the reference range of the trial site, serum sodium higher than the upper limit of the reference range of the trial site, serum sodium lower than 125mEq/L
- •Subjects with serum potassium higher than 6.0mEq/L and abnormal findings inappropriate for inclusion in the trial are observed by 12-lead ECG
- •Subjects who are unable to sense thirst or who have difficulty with fluid or food intake
- •Subjects who have participated in any other clinical trial or post-marketing clinical studies within 4 weeks prior to informed consent
- •Female subjects who are pregnant, possibly pregnant, or nursing, or who plan to become pregnant during the trial period
- •Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
研究组 & 干预措施
OPC-41061
Experimental
干预措施: OPC-41061 (Drug)
结局指标
主要结局
Change From Baseline in Daily Urine Volume
时间窗: Baseline and Day 14 (Intermittent Administration Period)
The daily urine volume at each timepoint and its change and the percent change from baseline will be summarized with descriptive statistics (number, mean, standard deviation \[SD\], minimum, median, maximum \[same for following parameters\]).
次要结局
- Change From Baseline in Total Fluid Removal Per Week by Dialysis(Baseline (pretreatment observation period) and Intermittent Administration Period (Day 10 to Day 15))
研究者
相似试验
已完成
2 期
Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal DialysisChronic Renal FailureNCT01895322Otsuka Pharmaceutical Co., Ltd.20
已完成
2 期
A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or HemodiafiltrationChronic Renal FailureNCT02331680Otsuka Pharmaceutical Co., Ltd.124
已完成
3 期
A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)Cardiac EdemaNCT00544869Otsuka Pharmaceutical Co., Ltd.52
终止
1 期
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple MyelomaMultiple Myeloma (MM)NCT04649073Otsuka Pharmaceutical Co., Ltd.11
已完成
3 期
A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)Edema, CardiacNCT00462670Otsuka Pharmaceutical Co., Ltd.110